June 16, 2005
MDX Announces Senior Management Change
For Immediate Release
Vancouver, BC, June 16, 2005 - MDX Medical Inc. (TSX.V: MDX) announces effective June 16, 2005, Barry Allen, Chairman, will assume the role of President and C.E.O. of the Company.
"I look forward to leading MDX Medical as we drive the development of our technologies towards commercial success," said Allen. "We have a strong business and technology team with significant depth and experience that we will continue to build on."
"I believe our recently acquired licence to use NIRS (near-infrared spectrophotometry) technology for the non-invasive diagnosis of bladder disease will drastically improve the quality of care for patients. This technology has the potential to displace the current highly invasive and costly procedure and become the standard of care for bladder disease."
MDX also announced the Board of Directors accepted the resignation of Mark Thomson from the position of President and Director. The Board wishes to thank Mr. Thomson for his contributions in the past year in leading the growth of the Company.
About MDX Medical
MDX Medical Inc.'s focus is on commercializing novel, innovative and leading edge medical device technologies for improved diagnosis and treatment of cancer and other prominent health disorders. The Company's business strategy is to acquire promising technologies that have reached the "proof of feasibility" or later stages of product development, complete the final stages of commercialization, obtain the required regulatory approvals and pursue strategic marketing partners. For more information about MDX, please visit our website at: www.mdxmedical.com.
On behalf of the Board,
"Barry Allen"
Chairman, MDX Medical Inc.
Certain information contained in this press release may be forward looking and is subject to unknown risks, which could cause actual results to differ materially from those, set forth or implied herein. Although the Company believes that the expectations reflected in such forward looking statements are reasonable, it can give no assurance that such expectations will prove correct.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Larry Horsburgh
Phone: (604) 694-7770, Ext. 112
Email: lhorsburgh@mdxmedical.com
|
